Desvenlafaxine Succinate ER — A Non-Hormonal SNRI Option

Route: Oral, extended-release tablet or capsule.

• Administer once daily, with or without food, at consistent daily timing.
• Swallow whole — do not crush, split, or chew; extended-release integrity must be maintained.
• Consistent timing optimizes steady-state plasma concentrations and minimizes intraday fluctuations.

Dosing is individualized by the prescribing clinician. Pharmacological reference dosing information:

• MDD (FDA-approved): 50 mg once daily; doses above 50 mg/day have not demonstrated additional antidepressant efficacy.
• Vasomotor symptoms (off-label): 50–100 mg/day studied; clinical evidence suggests meaningful reduction in hot flash frequency at 100 mg/day.
• Renal impairment: Reduce dose in moderate-to-severe renal impairment; consult prescribing guidelines.
• Tapering: Gradual dose reduction required on discontinuation to minimize withdrawal-emergent symptoms.

All dosing decisions are prescriber-directed and patient-specific.

• Desvenlafaxine succinate: Inhibits the serotonin transporter (SERT) and norepinephrine transporter (NET) with approximately 10:1 serotonin-to-norepinephrine selectivity ratio. Enhanced synaptic serotonin and norepinephrine availability modulates the hypothalamic thermostat (reducing vasomotor instability) and limbic structures (improving mood and affect). No clinically meaningful activity at muscarinic, alpha-adrenergic, or histamine receptors. As a non-hormonal agent, it does not affect estrogen, progesterone, or androgen receptor pathways.

Clinical Context: This preparation positions desvenlafaxine as a non-hormonal SNRI option for postmenopausal women with moderate-to-severe vasomotor symptoms (hot flashes, night sweats) who have contraindications to hormone therapy, such as personal or family history of hormone-sensitive cancers, thromboembolism, or patient preference. It is also prescribed for major depressive disorder. Randomized controlled trials show clinically significant reductions (up to 62%) in hot flash frequency versus placebo.

Monitoring:

• Baseline and periodic blood pressure assessment.
• Mood and suicidality monitoring per SNRI class labeling.
• Serum sodium in elderly or at-risk patients (SIADH risk).
• Fasting lipid panel: dose-dependent dyslipidemia may occur.
• Reassess therapeutic response and continued need at follow-up.

Contraindications:

• Hypersensitivity to desvenlafaxine or venlafaxine.
• Concurrent or recent (within 14 days) MAOI use.
• Linezolid or IV methylene blue co-administration.

Warnings & Precautions:

• Serotonin syndrome: risk with serotonergic co-medications.
• Blood pressure elevation: monitor at baseline and throughout treatment.
• Suicidality black box warning: increased risk in patients ≤24 years — monitor closely at initiation and dose changes.
• Angle-closure glaucoma risk in susceptible individuals.
• Increased bleeding risk with antiplatelet agents and anticoagulants.
• Neonatal adaptation syndrome with third-trimester exposure.

Drug Interactions:

• MAOIs (contraindicated)
• Serotonergic agents (triptans, tramadol, linezolid, St. John's Wort) — additive serotonin risk
• NSAIDs, aspirin, warfarin — increased GI/systemic bleeding risk

Common Side Effects: Nausea, dry mouth, constipation, insomnia, hyperhidrosis, dizziness, decreased appetite, sexual dysfunction, and blood pressure elevation. Nausea is most common in the first week and often resolves with continued therapy.

Store at controlled room temperature (20–25°C / 68–77°F). Keep away from moisture, heat, and light. Store in original container, tightly sealed. Keep out of reach of children. Use before the beyond-use date assigned by Genesis Compounding. Discard any unused or expired portions per pharmacy guidance.

Why is this called a 'non-hormonal' option?

Desvenlafaxine does not contain estrogen, progesterone, or any other hormone. It acts on neurotransmitter reuptake transporters (serotonin and norepinephrine), modulating the hypothalamus without hormonal receptor binding, making it an option for patients who cannot or prefer not to use hormone therapy.

Is this the same as Pristiq®?

This compounded preparation contains the same active ingredient (desvenlafaxine succinate) as Pristiq®. Compounding allows prescriber-directed customization of dose or formulation when commercially available options do not meet patient-specific needs. This product is not FDA-approved as a compounded preparation.

How long does it take to see an effect on hot flashes?

Clinical trials have demonstrated reductions in hot flash frequency within 1–4 weeks of initiation. Maximum benefit may take 4–12 weeks. Prescribers should reassess response at 4–8 week intervals.

Should I take this at the same time every day?

Yes. Consistent daily dosing maintains steady plasma drug levels and optimizes therapeutic effect while minimizing fluctuations that could precipitate symptoms.

What happens if I stop this medication abruptly?

Abrupt discontinuation may cause withdrawal-emergent symptoms including dizziness, nausea, headache, irritability, and flu-like symptoms. The prescriber should guide a gradual tapering schedule. Patients should never stop without medical guidance.